Moleculin Biotech Advances to Phase 3 in AML Treatment Trial

Moleculin Biotech (MBRX) has provided an announcement.

Moleculin Biotech, Inc. revealed in a recent press release their successful discussion with the FDA, paving the way for a Phase 3 trial of Annamycin, combined with Cytarabine, for treating acute myeloid leukemia (AML) patients unresponsive to initial therapies. The upcoming global “MIRACLE” trial will focus on patients who have relapsed or are refractory to induction therapy, signaling a significant step forward in AML treatment.

For an in-depth examination of MBRX stock, go to TipRanks’ Stock Analysis page.